Area of research
Clinical Biochemistry · Molecular Medicine
Research interest
Research interests include Bacterial Identification and Susceptibility Testing, Antibiotic Resistance in Bacteria, Antimicrobial Resistance in Staphylococcus, and Antibiotics Pharmacokinetics and Efficacy.
Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories
CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests
Two-Site Evaluation of the Colistin Broth Disk Elution Test To Determine Colistin <i>In Vitro</i> Activity against Gram-Negative Bacilli
Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 <i>Enterobacteriaceae</i> CLSI Breakpoints
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates
Multisite Evaluation of Cepheid Xpert Carba-R Assay for Detection of Carbapenemase-Producing Organisms in Rectal Swabs
Digital Quantification of DNA Replication and Chromosome Segregation Enables Determination of Antimicrobial Susceptibility after only 15 Minutes of Antibiotic Exposure
Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape
Clinical and Microbiological Aspects of β-Lactam Resistance in Staphylococcus lugdunensis
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Antimicrobial Susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans
Evaluation of Oxacillin and Cefoxitin Disk and MIC Breakpoints for Prediction of Methicillin Resistance in Human and Veterinary Isolates of Staphylococcus intermedius Group
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI Breakpoints
Phenotypic and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in a Health Care System in Los Angeles, California, from 2011 to 2013
Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Staphylococcus spp. and Enterococcus spp
The emerging problem of linezolid-resistant <i>Staphylococcus</i>
In Vitro Susceptibility Testing of Fluoroquinolone Activity Against Salmonella: Recent Changes to CLSI Standards